Prudential Financial Inc Zai Lab LTD Transaction History

Prudential Financial Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$23.14 - $49.68 $416,520 - $894,240	-18,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$27.77 - $64.4 $499,860 - $1.16 Million	18,000 New	18,000 $792,000
Q4 2021 Feb 14, 2022	SELL	$54.9 - $105.21 $1.18 Million - $2.26 Million	-21,500 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$105.0 - $178.37 $1.6 Million - $2.71 Million	-15,200 Reduced 41.42%	21,500 $2.27 Million
Q2 2021 Aug 16, 2021	BUY	$125.11 - $180.0 $938,325 - $1.35 Million	7,500 Added 25.68%	36,700 $6.5 Million
Q1 2021 May 12, 2021	BUY	$126.27 - $191.71 $2 Million - $3.03 Million	15,800 Added 117.91%	29,200 $3.9 Million
Q4 2020 Feb 16, 2021	BUY	$81.94 - $135.34 $537,444 - $887,695	6,559 Added 95.88%	13,400 $1.81 Million
Q4 2019 Feb 11, 2020	BUY	$29.79 - $43.06 $203,793 - $294,573	6,841 New	6,841 $284,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.48B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.